AUA Meeting Highlights

Preliminary results from a single-arm study demonstrated promising progression-free survival (PFS) and a clinically meaningful objective response rate (ORR) with the combination of pembrolizumab (Keytruda) and nab-paclitaxel (Abraxane) as second- or third-line therapy in patients with advanced urothelial carcinoma. Read More ›

Treatment with a combination of pembrolizumab (Keytruda) and enzalutamide (Xtandi) continues to show substantial activity in patients with metastatic castration-resistant prostate cancer (CRPC) who have already been treated with abiraterone (Zytiga), according to results of a recent clinical trial, which were presented during the virtual 2020 American Urological Association Annual Meeting. Read More ›

Circulating tumor DNA (ctDNA) analysis is a useful sequencing platform in metastatic castration-resistant prostate cancer (CRPC), and ctDNA alterations are detected in most patients with this type of prostate cancer, according to Justin Shaya, MD, Hematology/Oncology Fellow, UC San Diego Moores Cancer Center, CA. Read More ›

Healthcare reform and associated economic pressures “have changed the rules” for virtually all healthcare providers, and providers must reinvent strategic approaches and care delivery models in response to these changes, said Max Reiboldt, CPA, President and Chief Executive Officer, the Coker Group.

Read More ›

During her presentation at the 2016 AUA Practice Management Conference, Ms Maldonado reviewed some of the problem areas that have come to the attention of coding consultants for the AUA coding hotline.

Read More ›

Telemedicine Expands Its Reach into Urology Clinical Practice

Smartphone applications and online telehealth services have already proved popular in primary care, and their expansion into urology and other specialties is imminent. Some payers have begun to include telehealth requirements in contracts with hospitals and other providers, and studies have shown that telehealth reduces costs and can help to reduce hospital admission and readmission rates.

Read More ›

“The ultimate goal is to develop a viable strategy that incorporates aspects of traditional and contemporary approaches to meet the needs of the shifting healthcare landscape,” said Max Reiboldt, CPA, President and Chief Executive Officer, Coker Group, Alpharetta, GA.

Read More ›

Testosterone Replacement Does Not Increase Risk  for Prostate Cancer, Cardiovascular Disease

The study examined the association between testosterone replacement and prostate cancer using the National Prostate Cancer Register and the Prescribed Drug Register, which identified 38,570 men with a prostate cancer between 2009 and 2012, and 192,838 men without prostate cancer in the control group.

Read More ›

Strategies for Payer–Provider Contract Negotiation: Preparation and Data Are Crucial

Successful contract negotiation comprises a process involving a realistic self-assessment, an evaluation of your counterpart, and the development of a negotiating strategy, according to John M. Murphy, MD, MBA, Chief Executive Officer and Chief Medical Officer, Delaware Valley Urology, Mount Laurel, NJ.

Read More ›

AUA Addresses Integration of Advanced Practice Providers in Urology Practices
The skillful integration of advanced practice providers (APPs) into urology practices can help address issues related to the dwindling urologist workforce shortage and the aging of practicing urologists. Read More ›

Page 1 of 2

Urology Practice Management logo
Subscribe to Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or e‑Newsletters.

UPM e-Newsletter
UPM print publication